A prospective, multicenter study to evaluate the efficacy and safety of adding obinutuzumab (O-triple) to standard therapy consisting of mycophenolate mofetil (MMF) and glucocorticoids as an initial treatment regimen for patients with active lupus nephritis. (ChiCTR) - Oct 16, 2026 - P=N/A | N=70 | Not yet recruiting | Sponsor: Peking University First Hospital; Peking University First Hospital
New trial • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|